Authors
Daniel R Schonhaut, Corey T McMillan, Salvatore Spina, Bradford C Dickerson, Andrew Siderowf, Michael D Devous Sr, Richard Tsai, Joseph Winer, David S Russell, Irene Litvan, Erik D Roberson, William W Seeley, Lea T Grinberg, Joel H Kramer, Bruce L Miller, Peter Pressman, Ilya Nasrallah, Suzanne L Baker, Stephen N Gomperts, Keith A Johnson, Murray Grossman, William J Jagust, Adam L Boxer, Gil D Rabinovici
Publication date
2017/10
Journal
Annals of neurology
Volume
82
Issue
4
Pages
622-634
Description
Objective
18F‐flortaucipir (formerly 18F‐AV1451 or 18F‐T807) binds to neurofibrillary tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared in vivo 18F‐flortaucipir uptake in patients meeting clinical research criteria for PSP (n = 33) to normal controls (n = 46) and patients meeting criteria for Parkinson disease (PD; n = 26).
Methods
Participants underwent magnetic resonance imaging and positron emission tomography for amyloid‐β (11C‐PiB or 18F‐florbetapir) and tau (18F‐flortaucipir). 18F‐flortaucipir standardized uptake value ratios were calculated (t = 80–100 minutes, cerebellum gray matter reference). Voxelwise and region‐of‐interest group comparisons were performed in template space, with receiver operating characteristic curve analyses to assess single‐subject discrimination …
Scholar articles
DR Schonhaut, CT McMillan, S Spina, BC Dickerson… - Annals of neurology, 2017